Boundless Bio, Inc. Common Stock

Market Cap

$32M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.42+$0.20 (+16.39%)

Jun 5, 2026

52W High $1.6352W Low $1.01

Company Details

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed t...

CEO

—

IPO Date

Mar 28, 2024

Website

boundlessbio.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$56M

EPS (Diluted)

Free Cash Flow

-$48M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 8, 2026

FY 2025

Mar 9, 2026

Q4 2025

Mar 9, 2026

$0-100.0%

Q3 2025

Nov 5, 2025

Q2 2025

Aug 5, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee